The laboratory of Translational Imaging in Oncology (LITO) is a mixed research unit (UMR 1288) created on 1/1/2020 and supported by Inserm (=French NIH) and Institut Curie, the 1st cancer center in France. LITO is the continuation of the In Vivo Molecular Imaging lab (IMIV, UMR 1023) created in 2015 for 5 years (2015-2019).
LITO includes about 30 researchers, physicists, engineers, MDs, PharmDs, and technologists and is organized in two research groups with complementary activities:
- The first group is the Biomarkers for Phenotype Imaging group and is dedicated to the design and evaluation of innovative radiotracers for molecular imaging using Positron Emission Tomography (PET) to target molecular mechanisms key to cancer development. The goal of this group is twofold: first, better understand the mechanisms underlying cancer development and response or resistance to treatment, second optimize patient management through the identification of imaging phenotype assisting personalized medicine.
- The second group is the Integrated Radiomics for Precision Medicine group. This group takes davantage of PET biomarkers, but also biomarkers from Magnetic Resonance Imaging (MRI) and computer tomography (CT) and combines these biomarkers with other types of biomarkers (clinical, pathological, omics, from liquid biopsies) to profile the cancer disease for prognostic or predictive purpose. The models are also developed in such a way that they contribute to a better understanding of cancer-related processes.